Keros Therapeutics (KROS) Total Non-Current Liabilities (2019 - 2021)
Keros Therapeutics posted quarterly Total Non-Current Liabilities of $12.1 million for Q4 2021, up 57.66% year-on-year from $7.7 million in Q4 2020, and up 5.31% on a QoQ basis from $11.5 million in Q3 2021.
Keros Therapeutics (KROS) has 3 years of Total Non-Current Liabilities data on file, last reported at $12.1 million in Q4 2021.
- For the quarter ending Q4 2021, Total Non-Current Liabilities rose 57.66% year-over-year to $12.1 million; the trailing twelve-month figure through Dec 2021 stood at $12.1 million (up 57.66% YoY), and the FY2021 full-year result was $12.1 million, up 57.66% from the prior year.
- Total Non-Current Liabilities for Q4 2021 stood at $12.1 million, up from $11.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $12.1 million in Q4 2021 and bottomed at $7.4 million in Q3 2020.
- The 3-year median for Total Non-Current Liabilities is $9.3 million (2021), against an average of $9.4 million.
- The widest annual swing landed in 2020, when Total Non-Current Liabilities declined 25.93%; it then surged 57.66% in 2021.
- A 3-year view of Total Non-Current Liabilities shows it stood at $10.3 million in 2019, then fell by 25.93% to $7.7 million in 2020, then soared by 57.66% to $12.1 million in 2021.
- The last three Total Non-Current Liabilities figures came in at $12.1 million (Q4 2021), $11.5 million (Q3 2021), and $7.8 million (Q2 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 12.08 Mn |
| Sep 30, 2021 | 11.47 Mn |
| Jun 30, 2021 | 7.77 Mn |
| Mar 31, 2021 | 9.31 Mn |
| Dec 31, 2020 | 7.66 Mn |
| Sep 30, 2020 | 7.41 Mn |
| Jun 30, 2020 | 8.99 Mn |
| Mar 31, 2020 | 9.63 Mn |
| Dec 31, 2019 | 10.34 Mn |